Drug intelligence / Profile preview

UB-925

Development stage: Preclinical
Lead developer: United BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

UB-925 is a monoclonal antibody developed by United BioPharma (UBP) that targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). By binding to VEGFR2, UB-925 inhibits the interaction between VEGF and its receptor, thereby blocking VEGF/VEGFR2-mediated signaling pathways essential for tumor angiogenesis. This mechanism is intended to suppress the growth and metastasis of solid tumors by limiting their blood supply. UB-925 is currently in preclinical development for the treatment of various cancers, including gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on UB-925.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UB-925.

Explore the full profile